Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Second-generation kinase inhibitors.

Bert M Klebl1, Gerhard Müller

  • 1GPC Biotech AG, Max-Lebsche-Platz 32, D-81377 Munich, Germany. Bert.Klebl@gpc-biotech.com

Expert Opinion on Therapeutic Targets
|September 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Translation and validity testing of the Self-Assessment of Nursing Informatics Competencies Scale].

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen·2026
Same author

Towards selective peptide deformylase inhibitors: A mass spectrometry-based evaluation of in cellulo activity of actinonin and bromoindole derivatives.

European journal of medicinal chemistry·2026
Same author

Jammed disks of two sizes in a channel: Segregation driven by steric forces.

Physical review. E·2026
Same author

Diagnostic test accuracy of the Emergency Severity Index: a systematic review and meta-analysis.

European journal of emergency medicine : official journal of the European Society for Emergency Medicine·2025
Same author

[Safety concerns and speak-up in patient care from the perspective of nursing assistant trainees in Tyrol - a multicenter exploratory quantitative cross-sectional study].

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen·2025
Same author

Interrater reliability and practicability of the German version of the Ghent Global Incontinence-Associated Dermatitis Categorization Tool.

Pflege·2025

Kinase inhibitors are revolutionizing cancer treatment, with drugs like imatinib targeting specific kinases. Ongoing research and new technologies are advancing spectrum-selective inhibitors for anticancer therapies.

Area of Science:

  • Pharmaceutical industry
  • Oncology
  • Drug development

Background:

  • Kinase inhibitors represent a significant shift in pharmaceutical development, particularly for signal transduction therapies.
  • Small-molecule kinase inhibitors are gaining prominence in cancer research.
  • Three key drugs—imatinib, gefitinib, and erlotinib—have successfully reached the market for treating specific cancers.

Purpose of the Study:

  • To highlight the growing importance of kinase inhibitors in cancer therapy.
  • To discuss the impact of imatinib, gefitinib, and erlotinib as pioneering targeted drugs.
  • To introduce the emergence of novel chemogenomic and chemoproteomic technologies in kinase inhibitor research.

Main Methods:

  • Review of current clinical development of kinase inhibitor candidates.

Related Experiment Videos

  • Analysis of the mechanism of action of marketed kinase inhibitors (imatinib, gefitinib, erlotinib).
  • Discussion of ongoing research and clinical trials involving first-generation kinase inhibitors.

    • Main Results:

    • Imatinib, gefitinib, and erlotinib target specific, dysregulated kinases relevant to cancer.
    • These drugs are considered front-runners in targeted kinase inhibitor therapy.
    • Significant insights are being gained from ongoing research and clinical trials.

    Conclusions:

    • Kinase inhibitors are a rapidly advancing area in cancer research and treatment.
    • The development of spectrum-selective inhibitors is a key focus for future anticancer therapies.
    • Novel technologies are emerging to support the development of targeted kinase inhibitors.